Summary Two faecal occult blood tests (FOBTs), Hemoccult II (guaiac based) and Hemeselect (immunochemical) were compared in a population screening for colorectal cancer on 24 282 subjects aged 40-70. Hemeselect was interpreted according to a lower (+ and +) and a higher (+) positivity threshold. A total of 8008 compliers were enrolled in the study. Positivity rates: Hemoccult=6.0%, Hemeselect (+ and ±) = 8.2%, Hemeselect (+) = 3. 1%. Among FOBT-positive subjects complying with the diagnostic work-up, 22 had colorectal cancer (17 Hemeselect-positive (+), four Hemeselect-borderline (±), 15 Hemoccult-positive) and 166 subjects had adenomas (62 Hemeselect(+), 56 Hemeselect-borderline (±), 79 Hemoccult-positive) were detected. The positive predictive values (PPVs) for cancer were as follows: Hemoccult =3.7%, Hemeselect (+ and +) = 3.8%, Hemeselect (+) =8.4%. The PPVs for adenoma(s) were: Hemoccult = 19.7%, Hemeselect (+ and +) =21.4%, Hemeselect (+) =30.5%. The specificity for cancer was: Hemoccult =94.1%, Hemeselect (+ and +) = 92%, Hemeselect (+) = 97.1%. Ratios between detection rates of each test and expected incidence of colorectal cancer suggest that Hemoccult anticipates cancer diagnosis by approximately 2 years on average whereas the mean diagnostic anticipation of Hemeselect ranges between 2.5 and 3.2 years. Hemeselect is superior to Hemoccult as it is at least as effective but more efficient and acceptable than guaiac testing. Further evaluation of Hemeselect cost-effectiveness and sensitivity is needed in order to assess the optimal threshold of positivity and screening frequency.
In recent years several randomised (Mandel et al., 1993) or case-control studies (Selby et al., 1993; Wahrenrdorf et al., 1993; Lazovich et al., 1995) have reported guaiac-based faecal occult blood testing (Hemoccult II, SmithKline Diagnostics, San Jose, CA, USA) to reduce mortality from colorectal cancer (CRC). The Minnesota Colon Cancer Control Study (Mandel et al., 1993) has demonstrated that annual screening by rehydrated Hemoccult II is able to achieve a 33% reduction of mortality from CRC. Thus rehydrated Hemoccult may be taken to be the standard test for comparison of any other new faecal occult blood test (FOBT) in CRC screening. In the above-mentioned study rehydrated Hemoccult shows a high sensitivity for CRC (92.2%) but the corresponding specificity value is disappointingly low (90.4%), causing a high referral rate to colonoscopy (9.8%) and a relevant increase in screening costs. Another test, Hemeselect (SmithKline Diagnostics, San Jose, CA, USA), based on reverse-passive haemagglutination, has been (found to show) increased sensitivity as compared with Hemoccult (Castiglione et al., 1992; St John et al., 1993; Petrelli et al., 1994; Castiglione et al., 1994; Robinson et al., 1994) and also evidence of effectiveness in reducing mortality from CRC (Saito et al., 1995) . In our preliminary experiment (Castiglione et al., 1992; 38% and 48% (mean=44%) . In 1994 the new protocol was introduced in two municipalities previously screened by Hemoccult alone (9600 subjects aged 40-70). Attendance rates in these two municipalities were 37% and 38% (mean=37.5%).
In the present study only the first attendance with the new protocol was considered for each subject, provided both tests had been completed. Subjects previously screened by Hemoccult alone were included in our study provided at least 3 years had elapsed since the most recent screening.
Attenders were asked to collect faeces samples using Hemoccult kits on three consecutive bowel movement and Hemeselect kits on the first bowel movement only. Compliers were invited not to eat red meat 2 days before and during faeces samples collection. Returned specimens were developed in our laboratory usually within 1 week from faeces samples collection. Hemoccult was developed after rehydration and was considered positive when a blue colour appeared at least in one slide after application of one drop of developer. Hemeselect was interpreted at 1/8 dilution according to two positivity thresholds: positive (+) or borderline (±). After erythrocytes coated with anti-human haemoglobin antibodies were added to the diluted extract of faecal specimens, Hemeselect reactions were considered negative when no agglutination was evident. Reactions were considered as borderline (±) when erythrocytes formed a ring around a compact button, slightly greater in diameter than in the negative control well, with slight peripheral agglutination. Hemeselect was considered positive (+) when erythrocytes formed a ring greater in diameter and thinner than that in the negative control well or appeared filmy and spread out to uniformly cover the bottom of the well with or without centripetal sliding.
Subjects who were negative on both Hemoccult and Hemeselect tests were invited to a repeat screening after 2 years, and to visit their family doctors about any complaint occurring during that interval. Subjects with a positive Hemoccult and/or a positive/borderline Hemeselect test were invited to undergo pancolonoscopy. Double contrast barium enema was undertaken when pancolonoscopy was not possible. FOBT-positive subjects who did not complete the diagnostic work-up within 3 months from the date of testing were assumed as lost to follow-up for the purposes of the study.
Positivity rates of rehydrated Hemoccult or Hemeselect (+ and +) or (+ only) were calculated in the overall series and according to age.
Corresponding positive predictive values (PPVs) for cancer and/or adenomas and detection rates for cancer were calculated after exclusion of those FOBT-positive subjects who did not complete the diagnostic work-up.
Specificity for cancer was calculated as the proportion of subjects without cancer who were negative on each test independently of the performance of any diagnostic workup. According to this approach, subjects with both Hemoccult and Hemeselect-negative tests not undergoing any diagnostic assessment were assumed to be free of CRC. This assumption (Morrison, 1985, pp. 142-144) is justified since the frequency of CRC in the general population, especially in FOBT-negative subjects, is sufficiently low to allow a satisfactory estimate of specificity by taking as nondiseased all subjects not found to have CRC. FOBT-positive subjects not undergoing any diagnostic work-up were assumed as negatives as far as specificity for cancer was concerned.
Differences in positivity rates, PPVs and specificity of Hemoccult and Hemeselect were checked by the chi-square test, statistical significance being set at P<0.05.
The ratio between detection rate (prevalence) and expected incidence of CRC was calculated for each test. The expected incidence was estimated by means of the age -sex specific incidence rates of CRC in the Province of Florence (Zanetti and Crosignani, 1992) .
The 95% confidence interval for proportions was calculated using the normal approximation to the binomial; when the normal approximation was not valid, the exact confidence intervals were calculated. The 95% confidence intervals for the prevalence-incidence (P/I) ratios were calculated assuming a Poisson distribution for the numerators of the prevalence rates.
The relative sensitivity between tests (Morrison, 1985, pp. 62-64) ) were calculated and then tested by means of the McNemar test (McNemar, 1947 (Castiglione et al., 1994) .
In the present study 1-day Hemeselect was interpreted according to two different thresholds of positivity. When a lower positivity threshold (+ and +) of Hemeselect is considered, the positivity rate is significantly higher whereas specificity is significantly lower compared with Hemoccult. Nevertheless, such an increase in referral rate for colonoscopy and of overall screening costs may be acceptable in our experience, as the PPV for cancer and/or adenomas was comparable with that of Hemoccult and a larger number of cancers and adenomas were detected. It is noteworthy that of the 12 Hemeselect-detected Dukes' A cancers, seven were The prevalence-incidence (P I) ratio is considered to be an indicator of the mean sojourn time of cancer in the preclinical detectable phase. Assuming an exponential distribution. the P I ratio is an estimate of the mean lead time of a screening test. i.e. the time period by which the diagnosis of cancer has been anticipated on average (Day et al.. 1988 ).
In our data this figure is hardly higher than 2 as far as Hemoccult is concerned. This fact is consistent with the little, non-significant reduction in mortality from CRC in the biennial arm of the Minnesota Colon Cancer Control Study (Mandel et al., 1993) . In our series a longer protective effect of Hemeselect as compared with Hemoccult is suggested as the P I ratio of this test in the overall series is 2.5 or 3.2 according to the higher (-+) or the lower (+ and +) Hemeselect positivity threshold respectively.
Our data confirm a very low occurrence of colonic neoplasms in average risk subjects under the age of 50. This makes screening in this age group highly questionable for cost-effectiveness considerations and has persuaded us to modify the age limits of the inVited population in our programme.
The exact impact of Hemeselect testing on screening costeffectiveness needs to be carefully evaluated and will be the subject of a separate report.
Further efforts for the evaluation of Hemeselect sensitivity for CRC will be necessary in the future in order to assess the optimal positivity threshold and frequency of Hemeselect testing.
